NEW YORK, October 11, 2017 /PRNewswire/ --
If you want a Stock Review on NXTM, MDXG, HOLX, or WMGI then come over
Lawrence, Massachusetts headquartered Nxstage Medical Inc.'s stock finished Tuesday's session 0.62% higher at $27.54 with a total trading volume of 1.01 million shares. The stock has gained 11.95% over the past three months. The Company's shares are trading above their 200-day moving average by 4.47%. Moreover, shares of Nxstage Medical, which develops, manufactures, and markets products and services for patients suffering from chronic or acute kidney failure, have a Relative Strength Index (RSI) of 40.91. NXTM complete research report is just a click away at: http://dailystocktracker.com/registration/?symbol=NXTM
Shares in Marietta, Georgia headquartered MiMedx Group Inc. rose 5.38%, ending yesterday's session at $12.35. A total volume of 5.00 million shares was traded, which was above its three months average of 2.26 million shares. The stock has gained 35.12% over the past twelve months and 39.39% on an YTD basis. The Company's shares are trading above their 200-day moving average by 1.85%. Moreover, shares of MiMedx, which develops and markets regenerative biologics utilizing human placental tissue allografts with patent-protected processes for various sectors of healthcare, have an RSI of 44.18.
On October 06th, 2017, MiMedx announced that it will present at the Janney Osteoarthritis Pain Conference in New York. Michael J. Senken, CFO, and Mark Landy, SVP-Strategic Initiatives, are scheduled to present on October 11th, 2017, at 9:30 a.m. ET at The Union League Club. A webcast of this presentation will be available on the Company's website. The complimentary report on MDXG can be downloaded at: http://dailystocktracker.com/registration/?symbol=MDXG
On Tuesday, Marlborough, Massachusetts headquartered Hologic Inc.'s stock saw a decline of 0.08%, to close the day at $36.86. A total volume of 2.43 million shares was traded. The stock is trading below its 50-day moving average by 3.74%. Additionally, shares of Hologic, which develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the US, Europe, the Asia-Pacific, and internationally, have an RSI of 39.78.
On October 03rd, 2017, Hologic announced plans to release its financial results for Q4 FY17 on November 08th, 2017, after the market closes. In conjunction with the release, management will host a conference call that same day at 4:30 p.m. ET. A live webcast of the call will be available on the Company's website.
On October 09th, 2017, research firm Stifel reiterated its 'Buy' rating on the Company's stock with a decrease of the target price from $48 a share to $45 a share. Sign up for your complimentary research report on HOLX at: http://dailystocktracker.com/registration/?symbol=HOLX
Wright Medical Group
Shares in Amsterdam, the Netherlands headquartered Wright Medical Group N.V. ended the day 0.38% higher at $26.18. A total volume of 1.47 million shares was traded, which was above their three months average volume of 1.07 million shares. The stock has gained 13.93% since the start of this year. The Company's shares are trading below their 50-day moving average by 4.93%. Furthermore, shares of Wright Medical, which designs, manufactures, markets, and sells extremities and biologics products in the US, Europe, Middle-East, Africa, and internationally, have an RSI of 44.38. Get free access to your research report on WMGI at: http://dailystocktracker.com/registration/?symbol=WMGI
Daily Stock Tracker:
Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
DST has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected] . Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit: http://dailystocktracker.com/disclaimer/
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: [email protected] Phone number: (207)331-3313 Office Address: 377 Rivonia Boulevard, Rivonia, South Africa
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
Subscribe to our Free Newsletters!
Sarcoma, is a cancer that may arise from several soft-tissues or bone. Treatment in early stages is ...
A wonder drug, soda bicarb or baking soda can be used for skin, teeth, hair, kidneys and much more ...
Melasma, also called as chloasma, is a skin hyperpigmentation problem characterized by brown spots ...View All